Abstract:CD4 mimics are small molecules that inhibit the interaction of gp120 with CD4. We have developed several CD4 mimics. Herein, hybrid molecules consisting of CD4 mimics with a long alkyl chain or a PEG unit attached through a self-cleavable linker were synthesized. In anti-HIV activity, modification with a PEG unit appeared to be more suitable than modification with a long alkyl chain. Thus, hybrid molecules of CD4 mimics, with PEG units attached through an uncleavable linker, were developed and showed high anti-HIV activity and low cytotoxicity. In investigation of pharmacokinetics in a rhesus macaque, a hybrid compound had a more effective PK profile than that of the parent compound, and intramuscular injection was a more useful administration route to maintain the high blood concentration of the CD4 mimic than intravenous injection. The presented hybrid molecules of CD4 mimics with a PEG unit would be practically useful when combined with a neutralizing antibody.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01153</a>.Experimental procedures of compound synthesis including characterization data, a calibration curve of YIR-821·2TFA used to calculate PK in a rhesus macaque, degradation experiments of the hybrid molecule 45 in the PBS solution (pH 7.4) at 37 °C, a calibration curve of the hybrid molecule 58·2TFA used to calculate PK in a rhesus macaque by iv injection, a calibration curve of 58·2TFA used to calculate PK in a rhesus macaque by im injection, the structures of YIR-821 and compound 58 docked in gp120, HPLC analysis of evaluation of the biological stability of compound 58·2TFA treated with human liver microsomes, FACS analysis of EGFP and HIV-1 JR-FL envelope (Env) expressing HEK293T cells treated with anti-CD4i antibodies, and inhibition of gp120-CD4 binding by compound 58 and YIR-821 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_001.pdf">PDF</a>)Molecular formula strings of 2–22, 24, 30, 32, 35, 36, 38–46, 49, 50, 54, 58, and 62 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors

Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors

Flexibility of small molecular CD4 mimics as HIV entry inhibitors

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Multitargeted Drug Design Strategy for Discovery of Short-Peptide-based HIV-1 Entry Inhibitors with High Potency

Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.

Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

Soluble-type small-molecule CD4 mimics as HIV entry inhibitors

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41

Artificial Peptides Conjugated with Cholesterol and Pocket-Specific Small Molecules Potently Inhibit Infection by Laboratory-Adapted and Primary HIV-1 Isolates and Enfuvirtide-Resistant HIV-1 Strains.